“…RvD1, 17R-RvD1, RvD3, 17R-RvD3, RvD5, RvE1, and 18S-RvE1 can combine with the G protein-coupled receptor (GPR32) expressed in monocyte-macrophages, lymphocytes, endothelial cells, and vascular smooth muscle cells, while GPR18/DRV2 is a novel discovered receptor of RvD2 expressed in macrophages, neutrophils, and monocytes [ 55 , 56 ]. In addition, RvD1, 17R-RvD1, and RvD3 can also combine with the G protein-coupled formyl peptide receptor 2 (ALX/FPR2) to produce anti-inflammatory effects [ 57 , 58 , 59 ]. Leukotriene B4 receptor 1 (BLT1) expressed in lymphocytes and leukocytes and ChemR23 expressed in NK cells, macrophages, epithelial cells, and dendritic cells have been proven to be the receptors of RvE1, 18S-RvE1, and RvE2 through target screening [ 60 , 61 ].…”